UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

A new study by UCSF researchers reveals that long-acting injectable treatments offer a promising alternative for HIV patients who find it challenging to adhere to daily pill regimens. This ...

It is better for your health to begin HIV treatment sooner, rather than later. There are some fixed-dose pills that combine two or three antiretroviral drugs from more than one drug class. These allow ...

The combination of tenofovir, FTC, and efavirenz might soon be available in a single pill. For years, effective antiretroviral treatment has required HIV-positive patients to take a large handful ...

The FDA just approved a new combination of drugs to treat HIV. The treatment combines three drugs into one daily pill: bictegravir, emtricitabine and tenofovir alafenamide. The new approval could ...

This study highlights that a once-daily single-pill antiretroviral regimen can lead to successful virologic suppression among homeless or marginally housed individuals. Presumably, patients who ...

with a trial demonstrating that people receiving this drug had 90 percent less risk of contracting HIV compared with oral pills. Yet access has been the major hurdle. Last month a new study ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UC San Francisco has found. The strategy could also help stop the spread ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UCSF has found. The strategy could also help stop the spread of HIV ...